Reviewing MetaVia (MTVA) & The Competition

MetaVia (NASDAQ:MTVA) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its peers? We will compare MetaVia to related companies based on the strength of its risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Profitability

This table compares MetaVia and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-212.00%	-107.21%
MetaVia Competitors	-1,425.99%	-589.65%	-28.81%

Risk & Volatility

MetaVia has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, MetaVia’s peers have a beta of 0.97, suggesting that their average stock price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for MetaVia and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1	0	2	0	2.33
MetaVia Competitors	5741	12161	37598	1166	2.60

MetaVia presently has a consensus target price of $7.50, suggesting a potential upside of 998.42%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 57.17%. Given MetaVia’s higher possible upside, analysts clearly believe MetaVia is more favorable than its peers.

Institutional and Insider Ownership

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 0.8% of MetaVia shares are owned by company insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares MetaVia and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MetaVia	N/A	-$27.59 million	-0.90
MetaVia Competitors	$966.95 million	-$43.53 million	11.81

MetaVia’s peers have higher revenue, but lower earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

MetaVia peers beat MetaVia on 8 of the 13 factors compared.

MetaVia Company Profile

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.